D2NL34 Stock Overview
A biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Denali Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$30.43 |
| 52 Week High | US$30.43 |
| 52 Week Low | US$16.04 |
| Beta | 1.37 |
| 11 Month Change | 20.32% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -18.39% |
Recent News & Updates
Recent updates
Shareholder Returns
| D2NL34 | BR Biotechs | BR Market | |
|---|---|---|---|
| 7D | 0% | -1.0% | 1.1% |
| 1Y | n/a | 12.2% | 8.5% |
Return vs Industry: Insufficient data to determine how D2NL34 performed against the BR Biotechs industry.
Return vs Market: Insufficient data to determine how D2NL34 performed against the BR Market.
Price Volatility
| D2NL34 volatility | |
|---|---|
| D2NL34 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 8.9% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in BR Market | 9.1% |
| 10% least volatile stocks in BR Market | 2.3% |
Stable Share Price: D2NL34 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine D2NL34's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 364 | Ryan Watts | www.denalitherapeutics.com |
Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases.
Denali Therapeutics Inc. Fundamentals Summary
| D2NL34 fundamental statistics | |
|---|---|
| Market cap | R$22.90b |
| Earnings (TTM) | -R$2.28b |
| Revenue (TTM) | R$6.89m |
3,325x
P/S Ratio-10.0x
P/E RatioIs D2NL34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| D2NL34 income statement (TTM) | |
|---|---|
| Revenue | US$1.27m |
| Cost of Revenue | US$422.61m |
| Gross Profit | -US$421.34m |
| Other Expenses | -US$1.69m |
| Earnings | -US$419.65m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.93 |
| Gross Margin | -33,255.09% |
| Net Profit Margin | -33,121.86% |
| Debt/Equity Ratio | 0% |
How did D2NL34 perform over the long term?
See historical performance and comparison